Cyman Therapy

Cyman Therapy is a UK-based biotechnology company focused on developing small molecule inhibitors for high-value, "undruggable" targets in oncology. Spun out from the University of Cambridge, the company leverages a proprietary fragment-based drug discovery platform to target protein-protein interactions. Their lead program focuses on the MYC oncoprotein, a critical driver in many cancers that has historically been difficult to target with conventional therapies. Cyman Therapy aims to disrupt the MYC-MAX interaction to provide new treatment options for patients with MYC-dependent tumors. The company is backed by prominent venture investors including Cambridge Enterprise and Parkwalk Advisors.